Publications by authors named "L Ricard"

Individuals with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have a high risk of developing other malignancies (OMs). The development of OMs may be associated with the advanced age of CLL/SLL patients, presence of a tumor-promoting microenvironment, immune alterations inherent to CLL/SLL, or chemotherapy. Importantly, the occurrence of OMs following frontline fludarabine, cyclophosphamide and rituximab (FCR) treatment is associated with a reduction in the overall survival (OS).

View Article and Find Full Text PDF
Article Synopsis
  • - Immune effector cell-associated hematotoxicity (ICAHT) is a significant and common side effect following CAR-T-cell therapy, particularly impacting patient recovery and health.
  • - The article discusses three cases where patients experienced severe ICAHT after receiving axicabtagene-ciloleucel (axi-cel) for diffuse large B-cell lymphoma, characterized by an increase in a specific type of lymphocyte in the bone marrow.
  • - Treatment with low-dose steroids successfully resolved the cytopenias (low blood cell counts) without harming the effectiveness of the cancer treatment.
View Article and Find Full Text PDF

The 2015 Paris agreement was established to limit Greenhouse gas (GHG) global warming below 1.5°C above preindustrial era values. Knowledge of climate sensitivity to GHG levels is central for formulating effective climate policies, yet its exact value is shroud in uncertainty.

View Article and Find Full Text PDF

Background: This study explores the impact of decentralized management on the sickness absence among healthcare professionals. Sickness absence is a reliable indicator of employees' wellbeing and it is linked to management quality. However, the influence of decentralized management on sickness absence has not been adequately studied.

View Article and Find Full Text PDF